| Literature DB >> 26879974 |
Kaifan Dai1,2, Salar N Khan1,2, Yimeng Wang2, Linling He2, Javier Guenaga1,2, Jidnyasa Ingale1,2,3, Christopher Sundling4, Sijy O'Dell5, Krisha McKee5, Ganesh Phad4, Martin Corcoran4, Richard Wilson1,2, John R Mascola5, Jiang Zhu1,2,3, Yuxing Li1,2, Gunilla B Karlsson Hedestam4, Richard T Wyatt1,2,3.
Abstract
The elicitation of HIV-1 broadly neutralizing antibodies following envelope glycoprotein (Env) vaccination is exceedingly difficult. Suboptimal engagement of naïve B cells is suggested to limit these low frequency events, especially at the conserved CD4bs. Here, we analyzed CD4bs-directed monoclonal antibodies (mAbs) elicited by YU2 gp140-foldon trimers in a non-human primate by selective sorting using CD4bs "knock out" trimers. Following two inoculations, the CD4bs-directed mAbs efficiently recognized the eliciting immunogen in their affinity-maturing state but did not recognize CD4bs-defective probes. We reverted these mAbs to their most likely inferred germline (igL) state, leaving the HCDR3 unaltered, to establish correlates of in vitro affinity to in vivo activation. Most igL-reverted mAbs bound the eliciting gp140 immunogen, indicating that CD4bs-directed B cells possessing reasonable affinity existed in the naïve repertoire. We detected relatively high affinities for the majority of the igL mAbs to gp120 and of Fabs to gp140, which, as expected, increased when the antibodies 'matured' following vaccination. Affinity increases were associated with slower off-rates as well as with acquisition of neutralizing capacity. These data reveal in vitro binding properties associated with in vivo activation that result in functional archiving of antigen-specific B cells elicited by a complex glycoprotein antigen following immunization.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26879974 PMCID: PMC4754655 DOI: 10.1038/srep20987
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Schematic of immmunization regimen, mAb isolation and analysis “pipeline”.
(A) Seven mAbs isolated following 2 Env trimer inoculations and resulting characterization at the genetic and protein level as shown. (B) Genetic analysis using the current NHP data base revealed mAb levels of SHM ranging from 0.75% to 7.63% at the nucleotide level as indicated and higher SHM when calculated at the amino acid level. New genes identified by genomic sequencing are labeled as ‘*’followed by numbers 01, 02 or 03.
Figure 2ELISA Env recognition properties of the mature and igL-reverted antibodies.
(A) Binding of mature and igL IgG to soluble, monomeric YU2 gp120 (left) and isogenic gp120 possessing a non-conservative D368R mutation in the CD4bs (right) by ELISA. Mature and igL binding to JRFL gp140-F and CAP244 gp140-F are shown as two panels on the right. (B) Binding to clade B YU2 gp140-F trimers by the mature and igL mAbs (left) and to gp140-F D368R (right). Binding was abolished to D368R CD4bs “knockout” version of the YU2 gp140-F trimer (A and B panels on the left). The igL versions did not recognize the JRFL gp140-F D368R, consistent with naïve-state recognition of the CD4bs (B, panel on the right).
Figure 3igL and mature antibody binding kinetics to gp120 monomer and gp140-F immunogen.
(A) Schematic of the BLI assay formats. IgGs were captured on anti-human IgG Fc BLI biosensors and monomeric gp120, the analyte in solution and gp140-F was captured on streptavidin biosensors with the analyte in solution being Fabs. (B) Binding curves of selected igL IgG and their corresponding mature mAbs to SEC-purified monomeric YU2 gp120 (left) and to YU2 gp140-F (right). Data points are shown in black and the corresponding fits are shown in red. The Env concentrations used ranged from 500 nM to 1μM initial concentration as indicated above the highest concentration curve. 1:2 serial dilutions were used subsequently. Mature antibodies in general have higher affinity to gp120, displaying faster on-rates and slower off-rates. (C) Binding kinetics of the mature and igL IgG and Fabs to YU2 gp120 and YU2 gp140-F trimers respectively. (D) SPR binding kinetics were determined and used to derive affinities of both the mature and igL Fabs, with fold differences indicated (right), and the schematic of the method and binding curves are shown (left).
Figure 4igL antibodies derived from sibling CDR3s.
The CDR3 regions of the HC and the LC of the original igL versions (in green) are shown at the top for each gene family. The CDR3 regions of the siblings isolated are shown below with amino acid differences indicated. Sibling igL versions are labelled (i)–(x) (A). A schematic alignment depicting one representative sibling igL version as made is shown (B). Binding curves and fits of sibling igL binding to SEC purified monomeric gp120 by Octet (C). The kD values of the sibling igLs compared to the original igLs are shown (D).
Figure 5Binding properties of selected gL-reverted mAbs is HCDR3-dependent Residues in the HCDR3 region of two selected igL binders were mutated in specific sites within their respective HCDR3s to asses binding to soluble YU2 gp140-F trimers.
These mutations were guided by previous modeling information of mature GE136 and GE148 and their interactions with gp120. (A) Fv regions of GEBT391 and GEBT404 were generated by the Protein Homology/Analogy Recognition Engine (Phyre) and the model was used in the computational protein docking program, ClusPro2 to generate models of GEBT391 (left) and GEBT404 (right) binding to gp120. The gp120 core is modeled inside the structure of BG505 SOSIP (PDB ID: 4TVP) to depict orientation in the context of the trimer. Both antibodies approach the gp120 CD4bs “from the side”, creating clash with the adjacent protomer in the trimer context. This clash is shown by the partial burial of the Hc within the protomer colored light blue (middle). The residues involved in recognition are depicted with a white dashed box (A) and are shown magnified (B). GEBT 391 residue Y107 and GEBT 404 residue V107 interact with D368 of gp120. (C) Mutating residues 106 and 107 in both mAbs eliminated recognition but changing the residue 109, which is relatively distal to the CD4 binding loop of gp120, resulted in only a partial reduction in binding.
Figure 6Neutralization of mature, chimeric and gL mAbs to HIV-1.
Neutralization IC80 data of the mature mAbs (left) and gL-reverted mAbs (right) are shown and color-coded for concentrations regarding potency as indicated. Fab neutralization data and the IC50 values are tabulated in Fig. S12.